Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 3,970 Avalo Therapeutics, Inc. shares (Form 4)

Traded Apr 6, 2026 · Filed Apr 8, 2026

On Apr 6, 2026, Doyle Mittie (Chief Medical Officer) sold 3,970 Avalo Therapeutics, Inc. shares at US$18.01 for US$71,500 under a trading plan, leaving 3,622 shares. Filed Apr 8, 2026 (Form 4).

Sold
3,970 shares
Price
US$18.01
Value
US$71,500
Holding after
3,622 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 6, 2026Common StockOption exercise3,970US$12.657,592Direct
Apr 6, 2026Common StockSale3,970US$18.013,622Direct

Source

View original at SEC

Related